Accéder au contenu
Merck

miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells.

OncoTargets and therapy (2016-04-05)
Min Zhang, Bing-Bin Dong, Min Lu, Mei-Juan Zheng, He Chen, Jing-Zhen Ding, A-Man Xu, Yuan-Hong Xu
RÉSUMÉ

It has been previously reported that the deregulation of microRNAs in gastric cancer (GC) was correlated with the progression and prognosis. miR-429, a member of the miR-200 family, was previously shown to play an important role in human carcinomas. Our study shows that miR-429 is significantly downregulated in GC tissues compared with matched nontumor tissues. Overexpression of miR-429 in GC cells suppressed cell proliferation. Fascin-1 (FSCN1) was identified as one of the targets of miR-429 and knockdown of FSCN1 mimics the function of miR-429 overexpression. In conclusion, miR-429 acts as a tumor suppressor by targeting FSCN1, suggesting that miR-429 and FSCN1 can both be potential therapeutic targets of GC.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-Fascin Antibody, clone 55K2, clone 55K2, Chemicon®, from mouse